The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Open accessAbstract
Inflammation-triggered combination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60737-6 · Cited by 1,470
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Programmable materials and the nature of the DNA bond
Jones, M. R., Seeman, N. C., & Mirkin, C. A. (2015) · Science · doi:10.1126/science.1260901 · Cited by 1,347
Rolling circle amplification: a versatile tool for chemical biology, materials science and medicine
Ali, M. M., Li, F., Zhang, Z., Zhang, K., Kang, D.-K., Ankrum, J. A., Le, X. C., & Zhao, W. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60439j · Cited by 1,124
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
Self-citationSynthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Tohme, S., Yazdani, H. O., Al-Khafaji, A. B., Chidi, A. P., Loughran, P., Mowen, K., Wang, Y., Simmons, R. L., Huang, H., & Tsung, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1591 · Cited by 694
Inflammation and necrosis promote tumour growth
Vakkila, J., & Lotze, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1415 · Cited by 690
Metastasis as an evolutionary process
Turajlic, S., & Swanton, C. (2016) · Science · doi:10.1126/science.aaf2784 · Cited by 661
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Self-citationWang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201402996 · Cited by 566
Self-citationBiopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S.-R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 422
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
The effects of surgery on tumor growth: a century of investigations
Demicheli, R., Retsky, M. W., Hrushesky, W. J. M., Baum, M., & Gukas, I. D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn386 · Cited by 399
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Excisional surgery for cancer cure: therapy at a cost
Coffey, J., Wang, J., Smith, M., Bouchier-Hayes, D., Cotter, T., & Redmond, H. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01282-8 · Cited by 374
The Role of Matrix Metalloproteinases in Wound Healing
Armstrong, D. G., & Jude, E. B. (2002) · Journal of the American Podiatric Medical Association · doi:10.7547/87507315-92-1-12 · Cited by 350
Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery
Sun, W., Jiang, T., Lu, Y., Reiff, M., Mo, R., & Gu, Z. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5088024 · Cited by 329
Self-citationDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
The wound inflammatory response exacerbates growth of pre‐neoplastic cells and progression to cancer
Antonio, N., Bønnelykke‐Behrndtz, M. L., Ward, L. C., Collin, J., Christensen, I. J., Steiniche, T., Schmidt, H., Feng, Y., & Martin, P. (2015) · The EMBO Journal · doi:10.15252/embj.201490147 · Cited by 280
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Kwon, E. D., Foster, B. A., Hurwitz, A. A., Madias, C., Allison, J. P., Greenberg, N. M., & Burg, M. B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15074 · Cited by 222
Preparation and biomedical applications of programmable and multifunctional DNA nanoflowers
Lv, Y., Hu, R., Zhu, G., Zhang, X., Mei, L., Liu, Q., Qiu, L., Wu, C., & Tan, W. (2015) · Nature Protocols · doi:10.1038/nprot.2015.078 · Cited by 180
Gajanayake, T., Olariu, R., Leclère, F. M., Dhayani, A., Yang, Z., Bongoni, A. K., Banz, Y., Constantinescu, M. A., Karp, J. M., Vemula, P. K., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008778 · Cited by 171
Surgery, wound healing, and metastasis: Recent insights and clinical implications
Ceelen, W. P., Pattyn, P., & Mareel, M. M. K. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.008 · Cited by 151
Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mellati, M., Eaton, K. D., Brooks‐Worrell, B., Hagopian, W., Martins, R. G., Palmer, J. P., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0889 · Cited by 145
Biomaterials for enhancing anti-cancer immunity
Koshy, S. T., & Mooney, D. J. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.001 · Cited by 142
Roh, Y. H., Lee, J. B., Shopsowitz, K. E., Dreaden, E. C., Morton, S. W., Poon, Z., Hong, J., Yamin, I., Bonner, D. K., & Hammond, P. T. (2014) · ACS Nano · doi:10.1021/nn502596b · Cited by 128
Dendritic-cell vaccines on the move
Sabado, R. L., & Bhardwaj, N. (2015) · Nature · doi:10.1038/nature14211 · Cited by 90
Immune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Segatto, I., Berton, S., Sonego, M., Massarut, S., Perin, T., Piccoli, E., Colombatti, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2195 · Cited by 67
PROTEOLYTIC ENZYMES IN WOUND HEALING: THE ROLE OF ENZYMATIC DEBRIDEMENT
Sinclair, R. D., & Ryan, T. J. (1994) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.1994.tb01799.x · Cited by 66
Engineering DNA scaffolds for delivery of anticancer therapeutics
Sun, W., & Gu, Z. (2015) · Biomaterials Science · doi:10.1039/c4bm00459k · Cited by 61
Self-citationLiu, Q., Zhai, B., Yang, W., Yu, L., Dong, W., He, Y., Chen, L., Tang, L., Lin, Y., Huang, D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.221 · Cited by 56
Rolling Circle Replication for Engineering Drug Delivery Carriers
Sun, W., Lu, Y. C., & Gu, Z. N. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.27 · Cited by 17
Self-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Drug delivery systems and materials for wound healing applications
Saghazadeh, S., Rinoldi, C., Schot, M., Kashaf, S. S., Sharifi, F., Jalilian, E., Nuutila, K., Giatsidis, G., Mostafalu, P., Derakhshandeh, H., et al. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.008 · Cited by 842
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Metadata
- Authors
- Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2016-08-25
- Volume
- 28
- Issue
- 40
- Pages
- 8912-8920
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2507131421
- Cited by
- 344
- References
- 54
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.